Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Current Deferred Revenue (2024 - 2025)

Historic Current Deferred Revenue for Fennec Pharmaceuticals (FENC) over the last 2 years, with Q3 2025 value amounting to $248000.0.

  • Fennec Pharmaceuticals' Current Deferred Revenue changed 0.0% to $248000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $248000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $248000.0 for FY2024, which is N/A changed from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $248000.0 for Q3 2025, which was down 0.0% from $248000.0 recorded in Q2 2025.
  • Fennec Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $252000.0 during Q1 2024, with a 5-year trough of $248000.0 in Q3 2024.